Hyperfine, Inc. (HYPR) 股票分析
医疗保健Hyperfine, Inc.
$1.66
+$0.17 (+11.41%)
最后更新: 2026年5月26日
价格走势
暂无价格数据
分析
公司概述
Hyperfine, Inc. operates within the healthcare sector, specifically focusing on the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products, with a distinct technological approach involving the Swoop Portable MR Imaging System that operates at a lower magnetic field strength than conventional scanners. The company is positioned in the medical devices industry, which implies a specialization in specialized equipment used for diagnostic imaging rather than pharmaceuticals or consumer healthcare products. As of the latest data, Hyperfine, Inc. maintains a market capitalization of $119.21 million and employs a workforce of 102 individuals, while reporting a trailing twelve-month revenue of $13.56 million. These financial metrics indicate that the company functions as a micro-cap entity with a relatively small operational footprint, suggesting that its valuation is heavily influenced by its potential for future expansion rather than established profitability or massive revenue scale. The disparity between its small employee base and its current market cap highlights the market's pricing of the company based on the unique value proposition of its portable imaging technology rather than current cash flow generation.
财务健康
The company reported a trailing twelve-month revenue of $13.56 million, yet it recorded a net income of -$35,574,000 and an EBITDA of -$35,995,000, revealing a significant divergence between top-line sales and bottom-line profitability. This substantial gap between revenue and net income indicates a heavy cost structure where operating expenses, likely driven by research and development or manufacturing costs, far exceed the gross margins generated from product sales. The free cash flow stands at -$17,207,124, which signifies that the company is currently burning cash to fund its operations and growth initiatives, thereby limiting its immediate financial flexibility to fund internal expansion without external capital injection. Despite the negative profitability, the gross margin remains positive at 49.8%, suggesting that the core product pricing retains significant value after direct costs, whereas the operating margin of -144.9% and profit margin of -262.3% reflect severe inefficiencies or high overhead costs relative to the scale of operations. On the balance sheet, the company holds $35.09 million in cash against $314,000 in debt, resulting in a conservative leverage position supported by a debt-to-equity ratio of 0.77. The current ratio of 4.34 further demonstrates robust short-term liquidity, indicating that the company possesses more than four times the current assets necessary to cover its current liabilities. However, the return on equity of -79.0% and return on assets of -40.6% reveal that management has not yet achieved positive capital efficiency, as the company is destroying shareholder value through its current operational model rather than generating returns.
估值评估
Valuation multiples for Hyperfine, Inc. present a complex picture due to its lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -3.67, implying that the market is pricing the stock based on future earnings expectations that are currently negative or highly uncertain. The price-to-book ratio stands at 2.87, indicating that the market values the company at nearly three times its net asset value, which suggests a premium assigned to its intangible assets, proprietary technology, or future growth potential rather than its current book equity. Alternative valuation metrics such as a price-to-sales ratio of 8.79 and an EV/EBITDA of -2.33 further emphasize that investors are valuing the company primarily on its revenue generation capabilities rather than earnings power. Regarding trading range, the stock has a 52-week high of $2.22 and a 52-week low of $0.53, placing the current market price at a level that reflects significant volatility within this defined trading band. The beta of 1.06 indicates that the stock's price volatility moves in tandem with the broader market, suggesting that Hyperfine, Inc. does not offer a significant hedge against market-wide movements nor does it exhibit lower risk characteristics compared to the S&P 500 index.
Growth & Income
Hyperfine, Inc. demonstrated an impressive revenue growth rate of 128.0% year-over-year, while earnings growth is listed as N/A due to the company's continued losses, highlighting that revenue expansion is outpacing any potential for immediate earnings recovery. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings are theoretically available for reinvestment, though currently insufficient to cover losses. Consequently, the company reinvests its limited earnings and cash reserves into growth initiatives such as R&D and market expansion rather than distributing cash to shareholders. This profile characterizes Hyperfine, Inc. as a high-growth, non-income stock where capital appreciation relies entirely on the company's ability to eventually transition from a cash-burning stage to a profitable operational model.
同行比较
Hyperfine, Inc. (HYPR) 在医疗器械行业运营。以下是其与市值最接近的同行的比较:
| 公司 | 代码 | 市值 | 市盈率 |
|---|---|---|---|
| Hyperfine, Inc. | HYPR | $164.79M | N/A |
| Abbott Laboratories | ABT | $150.96B | 24.3 |
| Stryker Corporation | SYK | $119.99B | 36.2 |
| Medtronic plc | MDT | $99.63B | 21.7 |
医疗器械行业平均市盈率为60.2倍。Hyperfine, Inc.的市盈率为N/A。
本分析由AI生成,仅供参考,不构成投资建议。数据可能存在延迟或不准确。在做出投资决策之前,请务必进行自己的研究并咨询合格的财务顾问。
相关医疗器械股票
Abbott Laboratories
$150.96B
SYKStryker Corporation
$119.99B
MDTMedtronic plc
$99.63B
BSXBoston Scientific Corporation
$85.67B
EWEdwards Lifesciences Corporation
$50.41B
GEHCGE HealthCare Technologies Inc.
$29.19B
医疗保健热门股票
Eli Lilly and Company
$949.47B
JNJJohnson & Johnson
$554.09B
ABBVAbbVie Inc.
$376.54B
UNHUnitedHealth Group Incorporated
$342.24B
MRKMerck & Co., Inc.
$302.33B
关于Hyperfine, Inc.
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture archiving and communication system. It serves intensive care units, neurology offices, emergency departments, and comprehensive and primary stroke accredited facilities through direct sales and distributors in the United States, Canada, the United Kingdom, other European and Middle Eastern markets, Australia, and New Zealand. The company was founded in 2014 and is based in Guilford, Connecticut.
公司简介以英文显示。
访问官网 →